Menu

Chris Fall Picked to Lead the Department of Energy’s Office of Science

Fall served in the White House Office of Science and Technology Policy under President Barack Obama.

May 21, 2018
Jim Daley

ISTOCK, MINGZHEZHANG

On Thursday (May 18), President Donald Trump announced that he intends to nominate Chris Fall to lead the Department of Energy’s Office of Science. The office has a $6-billion budget and is the primary funder of physical sciences research, according to Science. The position is currently vacant. Physicist Cherry Murray, who was appointed to the post by President Barack Obama, served from December 18, 2015 until January 13, 2017.  

Fall is currently the principal deputy director of the Department of Energy’s (DOE) Advanced Research Projects Agency-Energy (ARPA-E), which develops new research findings into commercial products. Before joining the DOE, he worked at the Office of Naval Research (ONR) for six years, where he oversaw studies of new technology for naval systems. Prior to that, he served for three years at the White House Office of Science and Technology Policy (OSTP) during President Obama’s administration. In that role, Fall was the assistant director for Defense Programs and later, the acting lead for the National Security and International Affairs Division.

Fall was a faculty member in the bioengineering and anatomy and cell biology departments at the University of Illinois at Chicago before joining the Obama administration. During his career in research, he investigated energy production in neurons and the link between cellular signaling systems and cellular energy production. He holds a PhD in neuroscience from the University of Virginia.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.